The AHA Tuesday responded to a Centers for Medicare & Medicaid Services request for information regarding whether the agency should include exceptions to the electronic prescribing of controlled substances requirements in the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act.

The comments also respond to CMS’ question of whether it should impose penalties for noncompliance.

“While we do not oppose the general requirement for prescriptions for Schedule II-V controlled substances to be transmitted electronically, we are concerned with the timeline proposed for implementation as well as the potential for penalties for noncompliance within this timeline,” the AHA said. It urged CMS to approach the requirement “based on a holistic view of the full range of federal regulations that require hospital IT development, upgrade, testing and end-user training, and proceed with a period of enforcement discretion and lack of penalties.”

Related News Articles

Headline
The AHA May 12 responded to the Office of Management and Budget's April 11 request for information on regulatory relief, making 100 suggestions to the Trump…
Headline
The Trump administration May 5 issued two executive orders on pharmaceutical manufacturing and life-sciences research. The first executive order, "…
Headline
The Centers for Medicare & Medicaid Services today released a notice seeking public comment on the collection of information request regarding the State…
Headline
The Trump administration yesterday released executive orders on reducing anti-competitive regulatory barriers and repealing certain regulations deemed unlawful…
Headline
The Department of Health and Human Services Feb. 28 announced that it is rescinding its Nixon-era policy on inviting public participation when making rules and…
Headline
The Food and Drug Administration yesterday released recommendations for streamlining the approval process for medical devices that use artificial intelligence…